This study investigated the relationship between the dihydrouracil/uracil (UH2/U) plasma ratio, a surrogate marker of dihydropyrimidine dehydrogenase (DPD) activity, and 5-fluorouracil (5-FU)-related early toxicity. Plasma UH2/U ratios were determined in 68 colorectal cancer patients and 100 healthy controls. A cutoff value indicative of DPD deficiency was calculated using receiver operator characteristics. Patients experiencing toxicity were screened for the DPD G-to-A point mutation within the 5′-splicing donor site of intron 14 (IVS14+1G>A). Overall, 24/68 patients (35%) experienced toxicity (all grades) and abnormal UH2/U ratios were demonstrated in 21/24 (87.5%) patients. Drug concentrations up to 130 times the recommended level were found in 13/24 (54%) patients experiencing toxicity. One patient experiencing toxicity was a heterozygous carrier of the IVS14+1G>A mutation. A low UH2/U plasma ratio had a sensitivity of 0.87 and specificity of 0.93 for predicting 5-FU-induced toxicity. Systematic detection of DPD-deficient patients using the UH2/U ratio could optimize 5-FU-based chemotherapy and minimize life-threatening toxicity.
SaifMWHashmiSZeltermanD: Capecitabine vs continuous infusion 5-FU in neoadjuvant treatment of rectal cancer. A retrospective review. Int J Colorectal Dis2008; 23: 139–145.
5.
MilanoGEtienneMCRenéeN: Relationship between fluorouracil systemic exposure and tumour response and patient survival. J Clin Oncol1994; 12: 1291–1295.
6.
WeiXMcLeodHLMcMurroughJ: Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity. J Clin Invest1996; 98: 610–615.
7.
GamelinECDanquechin-DorvalEMDumesnilYF: Relationship between 5-fluorouracil (5-FU) dose intensity and therapeutic response in patients with advanced colorectal cancer receiving infusional therapy containing 5-FU. Cancer1996; 77: 441–451.
8.
DiasioRBBeaversTLCarpenterJT: Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity. J Clin Invest1988; 81: 47–51.
9.
van KuilenburgABHaasjesJRichelDJ: Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: Identification of new mutations in the DPD gene. Clin Cancer Res2000; 6: 4705–4712.
van KuilenburgABMeinsmaRZoetekouwL: Increased risk of grade IV neutropenia after administration of 5-fluorouracil due to a dihydropyrimidine dehydrogenase deficiency: High prevalence of the IVS14+1G>A mutation. Int J Cancer2002; 101: 253–258.
12.
van KuilenburgABVrekenPRivaD: Clinical and biochemical abnormalities in a patient with dihydropyrimidine dehydrogenase deficiency due to homozygosity for the C29R mutation. J Inherit Metab Dis1999; 22: 191–192.
13.
JohnsonMRHageboutrosAWangK: Life-threatening toxicity in a dihydropyrimidine dehydrogenase-deficient patient after treatment with topical 5-fluorouracil. Clin Cancer Res1999; 5: 2006–2011.
14.
JohnsonMRYanJShaoL: Semi-automated radioassay for determination of dihydropyrimidine dehydrogenase (DPD) activity. Screening cancer patients for DPD deficiency, a condition associated with 5-fluorouracil toxicity. J Chromatogr B Biomed Sci Appl1997; 696: 183–191.
15.
TakenoueTNagawaHMatsudaK: Relation between thymidylate synthase expression and survival in colon carcinoma, and determination of appropriate application of 5-fluorouracil by immunohistochemical method. Ann Surg Oncol2000; 7: 193–198.
16.
MorelABoisdron-CelleMFeyL: Identification of a novel mutation in the dihydropyrimidine dehydrogenase gene in a patient with a lethal outcome following 5-fluorouracil administration and the determination of its frequency in a population of 500 patients with colorectal carcinoma. Clin Biochem2007; 40: 11–17.
17.
CiccoliniJMercierCDahanL: Toxic death-case after capecitabine + oxaliplatin (XELOX) administration: Probable implication of dihydropyrimidine dehydrogenase deficiency. Cancer Chemother Pharmacol2006; 58: 272–275.
18.
SaltzLB: Understanding and managing chemotherapy-induced diarrhea. J Support Oncol2003; 1: 35–46.
19.
O'BrienBEKaklamaniVGBensonAB3rd: The assessment and management of cancer treatment-related diarrhea. Clin Colorectal Cancer2005; 4: 375–381.
20.
OkenMMCreechRHTormeyDC: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol1982; 5: 649–655.
21.
Di PaoloADanesiRCiofiL: Improved analysis of 5-fluorouracil and 5,6-dihydro-5-fluorouracil by HPLC with diode array detection for determination of cellular dihydropyrimidine dehydrogenase activity and pharmacokinetic profiling. Ther Drug Monit2005; 27: 362–368.
22.
BocciGDanesiRDi PaoloAD: Comparative pharmacokinetic analysis of 5-fluorouracil and its major metabolite 5-fluoro-5,6-dihydrouracil after conventional and reduced test dose in cancer patients. Clin Cancer Res2000; 6: 3032–3037.
23.
TerretCErdociainEGuimbaudR: Dose and time dependencies of 5-fluorouracil pharmacokinetics. Clin Pharmacol Ther2000; 68: 270–279.
24.
ErlichmanCFineSElhakimT: Plasma pharmacokinetics of 5-FU given by continuous infusion with allopurinol. Cancer Treat Rep1986; 70: 903–904.
25.
HeggieGDSommadossiJPCrossDS: Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res1987; 47: 2203–2206.
26.
SchalhornAKühlM: Clinical pharmacokinetics of fluorouracil and folinic acid. Semin Oncol1992; 19 (2 suppl 3): 82–92.
27.
JouliaJMPinguetFYchouM: Pharmacokinetics of 5-fluorouracil (5-FUra) in patients with metastatic colorectal cancer receiving 5-FUra bolus plus continuous infusion with high dose folinic acid (LV5FU2). Anticancer Res1997; 17: 2727–2730.
28.
ReignerBBleschKWeidekammE: Clinical pharmacokinetics of capecitabine. Clin Pharmacokinet2001; 40: 85–104.
29.
ReignerBWatanabeTSchüllerJ: Pharmacokinetics of capecitabine (Xeloda) in Japanese and Caucasian patients with breast cancer. Cancer Chemother Pharmacol2003; 52: 193–201.
30.
UrienSRezaíKLokiecF: Pharmacokinetic modelling of 5-FU production from capecitabine – a population study in 40 adult patients with metastatic cancer. J Pharmacokinet Pharmacodyn2005; 32: 817–833.
31.
MitchellFLynnSJackmanAL: Modified high-performance liquid chromatography assay for the measurement of 2′-deoxyuridine in human plasma and its application to pharmacodynamic studies of antimetabolite drugs. J Chromatogr B Biomed Sci Appl2000; 744: 351–358.
32.
RudbeckLDissingJ: Rapid, simple alkaline extraction of human genomic DNA from whole blood, buccal epithelial cells, semen and forensic stains for PCR. Biotechniques1998; 25: 588–590.
33.
VrekenPNiessenRWPetersM: A point mutation in an invariant splice acceptor site results in a decreased mRNA level in a patient with severe coagulation factor XIII subunit A deficiency. Thromb Haemost1995; 74: 584–589.
ChoiJKongKMozaffarT: Delayed oxaliplatin-associated neurotoxicity following adjuvant chemotherapy for stage III colon cancer. Anticancer Drugs2006; 17: 103–105.
36.
de GramontAFigerASeymourM: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol2000; 18: 2938–2947.
37.
GamelinEBoisdron-CelleMGuérin-MeyerV: Correlation between uracil and dihydrouracil plasma ratio, fluorouracil (5-FU) pharmacokinetic parameters, and tolerance in patients with advanced colorectal cancer: A potential interest for predicting 5-FU toxicity and determining optimal 5-FU dosage. J Clin Oncol1999; 17: 1105–1110.
38.
LuZZhangRDiasioRB: Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: Population characteristics, newly identified deficient patients, and clinical implications in 5-fluorouracil chemotherapy. Cancer Res1993; 53: 5433–5438.
39.
LuZZhangRDiasioRB: Population characteristics of hepatic dihydropyrimidine dehydrogenase activity, a key metabolic enzyme in 5-fluorouracil chemotherapy. Clin Pharmacol Ther1995; 58: 512–522.
40.
McMurroughJMcLeodHL: Analysis of the dihydropyrimidine dehydrogenase polymorphism in a British population. Br J Clin Pharmacol1996; 41: 425–427.
EtienneMCLagrangeJLDassonvilleO: Population study of dihydropyrimidine dehydrogenase in cancer patients. J Clin Oncol1994; 12: 2248–2253.
43.
ShestopalSAJohnsonMRDiasioRB: Molecular cloning and characterization of the human dihydropyrimidine dehydrogenase promoter. Biochim Biophys Acta2000; 1494: 162–169.
44.
NoguchiTTanimotoKShimokuniT: Aberrant methylation of DPYD promoter, DPYD expression, and cellular sensitivity to 5-fluorouracil in cancer cells. Clin Cancer Res2004; 10: 7100–7107.
45.
EzzeldinHHLeeAMMattisonLK: Methylation of the DPYD promoter: An alternative mechanism for dihydropyrimidine dehydrogenase deficiency in cancer patients. Clin Cancer Res2005; 11: 8699–8705.
46.
YuJMcLeodHLEzzeldinHH: Methylation of the DPYD promoter and dihydropyrimidine dehydrogenase deficiency. Clin Cancer Res2006; 12: 3864.
47.
MattisonLKFourieJHiraoY: The uracil breath test in the assessment of dihydropyrimidine dehydrogenase activity: Pharmacokinetic relationship between expired 13CO2 and plasma [2-13C]dihydrouracil. Clin Cancer Res2006; 12: 549–555.
48.
SaifMWJunejaVBlackG: Palmar–plantar erythrodysesthesia in patients receiving capecitabine and intratumor thymidine phosphorylase and dihydropyrimidine dehydrogenase: Is there a pharmacologic explanation?Support Cancer Ther2007; 4: 211–218.
49.
Van KuilenburgABVan LentheHVan GennipAH: Radiochemical assay for determination of dihydropyrimidinase activity using reversed-phase high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl1999; 729: 307–314.
50.
McLeodHLSluddenJHardySC: Autoregulation of 5-fluorouracil metabolism. Eur J Cancer1998; 34: 1623–1627.
51.
Di PaoloAIbrahimTDanesiR: Relationship between plasma concentrations of 5-fluorouracil and 5,6-fluoro-5,6-dihydrouracil and toxicity of 5-fluorouracil infusions in cancer patients. Ther Drug Monit2002; 24: 588–593.
